As of March 23, 2026, KalVista Pharmaceuticals's top three insider holders are Healthcare Capital Partners Iii, L.P. Venrock (TenPercentOwner, 5.30Mn shares), Benjamin L Palleiko (Chief Executive Officer, 451.81K shares), Christopher Yea (Chief Development Officer, 226.70K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Healthcare Capital Partners Iii, L.P. Venrock | 0 | 5,303,985 | 11 Apr, 2025 | |
| Benjamin L Palleiko | Chief Executive Officer | 451,815 | 0 | 10 Mar, 2026 |
| Christopher Yea | Chief Development Officer | 226,701 | 0 | 24 Feb, 2026 |
| Thomas Andrew Crockett | Ceo | 211,203 | 0 | 21 Feb, 2024 |
| Paul K. Audhya | Chief Medical Officer | 138,983 | 0 | 24 Feb, 2026 |
| Edward P. Feener | Chief Scientific Officer | 72,858 | 0 | 21 May, 2024 |
| Nicole Sweeny | Chief Commercial Officer | 47,003 | 0 | 24 Feb, 2026 |
| Brian Piekos | Chief Financial Officer | 13,762 | 0 | 24 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Mar, 2026 | Benjamin L Palleiko | Common Stock | A | 15,625 | - | 458,508 | D | M |
| 09 Mar, 2026 | Benjamin L Palleiko | Common Stock | D | 6,693 | $16.08 | 451,815 | D | S |
| 06 Mar, 2026 | Benjamin L Palleiko | Restricted Stock Unit | D | 15,625 | $0.00 | 125,001 | D | M |
| 21 Feb, 2026 | Paul K. Audhya | Common Stock | A | 6,250 | - | 139,337 | D | M |
| 21 Feb, 2026 | Nicole Sweeny | Common Stock | A | 6,250 | - | 45,978 | D | M |
| 21 Feb, 2026 | Christopher Yea | Common Stock | A | 3,750 | - | 227,923 | D | M |
| 21 Feb, 2026 | Brian Piekos | Common Stock | A | 5,000 | - | 15,529 | D | M |
| 21 Feb, 2026 | Benjamin L Palleiko | Common Stock | A | 23,250 | - | 452,917 | D | M |
| 22 Feb, 2026 | Nicole Sweeny | Common Stock | A | 5,000 | - | 50,978 | D | M |
| 22 Feb, 2026 | Christopher Yea | Common Stock | A | 3,125 | - | 231,048 | D | M |
| 22 Feb, 2026 | Paul K. Audhya | Common Stock | A | 5,000 | - | 144,337 | D | M |
| 23 Feb, 2026 | Benjamin L Palleiko | Common Stock | D | 10,034 | $15.57 | 442,883 | D | S |
| 23 Feb, 2026 | Brian Piekos | Common Stock | D | 1,767 | $15.57 | 13,762 | D | S |
| 21 Feb, 2026 | Benjamin L Palleiko | Restricted Stock Unit | D | 23,250 | $0.00 | 279,000 | D | M |
| 23 Feb, 2026 | Nicole Sweeny | Common Stock | D | 3,975 | $15.57 | 47,003 | D | S |
| 23 Feb, 2026 | Christopher Yea | Common Stock | D | 4,347 | $15.57 | 226,701 | D | S |
| 21 Feb, 2026 | Brian Piekos | Restricted Stock Unit | D | 5,000 | $0.00 | 60,000 | D | M |
| 23 Feb, 2026 | Paul K. Audhya | Common Stock | D | 5,354 | $15.57 | 138,983 | D | S |
| 21 Feb, 2026 | Nicole Sweeny | Restricted Stock Unit | D | 6,250 | $0.00 | 75,000 | D | M |
| 21 Feb, 2026 | Christopher Yea | Restricted Stock Unit | D | 3,750 | $0.00 | 45,000 | D | M |